bluuebunny/crossref_metadata_2025_split huggingface dataset:
Biprojectivity of generalized module extension and second dual of Banach algebras
Authors: Essmaili M. , Rejali A. , Salehi Marzijarani A. 
Published: December 2020

In this paper, we study biprojectivity of generalized module extension Banach algebras and second dual of Banach algebras. As a main result, we prove that if [Formula: see text] is a contractible closed ideal of [Formula: see text] such that [Formula: see text] is biprojective, then [Formula: see text] is biprojective. As a consequence, we give some results on biprojectivity of generalized module extension Banach algebras. Indeed, this is a generalization of results in [A. Ebaddian and A. Jabbari, Biprojectivity and biflatness of amalgamated duplication of Banach algebras, J. Algebra Its Appl. 19(7) (2020) 2050132 (15 pp.)]. Moreover, we show that if [Formula: see text] is biprojective and [Formula: see text] is a two-sided ideal of [Formula: see text] then [Formula: see text] is biprojective. This fact generalizes some known results in [M. S. Moslehian and A. Niknam, Biflatness and biprojectivity of second dual of Banach algebras, Southeast Asian Bull. Math 27(1) (2003) 129–133].
It’s All about the Coalition
Authors: Po Sovinda , Primiano Christopher B. 
Published: December 2020

Abstract
Since its creation in 2013, China’s Belt and Road Initiative (BRI) has received ample attention in the media and from government officials and scholars. Many different, and often polarising, views exist on BRI. While some view it as China’s grand strategic goal of remaking the world in its own image, others perceive it as consistent with the international system. Using interviews conducted in Cambodia and an examination of press sources, this article draws from the selectorate theory to examine both why the Cambodian government is siding with China regarding economic ties, specifically regarding BRI, and the impact that is having on popular perception in Cambodia. The small coalition in Cambodia that Hun Sen seeks to placate results in a negative view among a significant segment of the Cambodian populace regarding Cambodia’s relations with China, and Chinese investments in particular.
The Discourse of Guohua in Wartime Shanghai
Authors: Chan Pedith Pui 
Published: December 2020

Abstract
This article looks at artists’ engagement with artistic activities carried out in wartime Shanghai, with a particular focus on guohua (lit., ‘national painting’). Drawing on primary sources such as archival materials, diaries, paintings, magazines and newspapers, it explores the layered meanings attached to and social functions of guohua and the institutional structure of the Shanghai art world from the gudao (solitary island) period to the advent of full occupation from December 1941 onwards. As a symbol of Chinese elite culture, guohua continued to dominate the Shanghai art world with support from Wang Jingwei’s regime and the occupying Japanese, and was deemed the root of East Asian art and one of the crucial pillars of the East Asian renaissance in the discourse of the new order of East Asian art. Through closely examining the discourse of guohua in occupied Shanghai, this article advances our understanding of the production and consumption of art in wartime Shanghai by going beyond the paradigmatic binary of ‘collaboration’ and ‘resistance’.
Prevalence and Risk Factors Associated With Physical and/or Sexual Abuse Among Female Middle School Students: A Cross- Sectional Study in Kinshasa, DRC
Authors: Jonas Kakungu Assani Wa Mwenda , Tang Hai-yan , Deng Ling-chao , Yu Yizhen , Jean-Baptiste Kakoma N’dusu , Basile Kalema Kisungu , Opoku Sampson , Meng Heng 
Published: December 2020

This cross-sectional study sought to broaden the limited evidence on violence against young adolescent girls in non-conflict zones within the Democratic Republic of the Congo (DRC). Our goal was to estimate the prevalence of and the predictors of physical and/or sexual abuse among girls aged 11–18 years in Kinshasa. A total of 3,100 girls from five randomly selected schools were recruited by our team and given the questionnaires; among them, 3,011 (97.1%) participants completed the questionnaires and were included in the study for further analysis. After collecting all valid responses, the overall prevalence of physical and/or sexual abuse was sorted into the following categories: experienced physical abuse without a weapon (recorded by 70.1% of respondents), experienced physical abuse with a weapon (66.3% of respondents), attempted rape without penetration (76.5% of respondents), experienced attempted rape with penetration (73.9% of respondents), and experienced verbal sexual harassment (93.0%). Our logistic regression analysis indicated that specific kinds of living arrangements (such as only living with the father, mother, or a caregiver; odds ratio ranged 1.8 to 6.9) and places of residence (such as living in lower-class or middle-class districts; odds ratio ranged 1.7 to 6.2) had the strongest associations with higher risk pertaining to whether the respondent had experienced physical and/or sexual abuse in the past. Meanwhile, factors such as the students’ level of education (both middle grade and upper grade) and occupation of the father (specifically whether holding a part-time job or retired) were deemed to be more protective. However, physical and/or sexual abuse prevalence was found to be high among middle school girls in Kinshasa. Therefore, we recommend that drastic policies and strategies aimed at socioeconomic issue and living condition ameliorations among families should be implemented to curtail physical and sexual abuse in the nonconflict zones of the DRC.
Emphysematous epididymo-orchitis: An unusual case report
Authors: Agrawal Akshat , Mohanty Sudhansu Sekhar , Sen Kamal Kumar 
Published: December 2020

Introduction Emphysematous epididymo-orchitis in the young to middle age groups without any comorbidity like diabetes or metabolic disorders is an uncommon entity. Case report We present a case of a nondiabetic young patient, diagnosed with emphysematous epididymo-orchitis as a sequela to urinary tract infection. Discussion Clinically differentiating diagnoses of the acute scrotum may be difficult and ultrasound can be used reliably as the initial modality showing the presence of air for early diagnosis. Conclusion Nondiabetic young patients without any metabolic disorder should also be suspected for emphysematous epididymo-orchitis in the setting of the acute scrotum. An ultrasound examination can predict its presence with confidence.
Association between congenital thrombophilia and outcomes in pulmonary embolism patients
Authors: Lian Tian-Yu , Lu Dan , Yan Xin-Xin , Tan Jiang-Shan , Peng Fu-Hua , Zhu Yong-Jian , Wei Yun-Peng , Wu Tao , Sun Kai , Jiang Xin , Hua Lu , Jing Zhi-Cheng 
Published: December 2020

Abstract
The prevalence and distribution of congenital thrombophilia is still unclear in patients with pulmonary embolism (PE). We aimed to determine the prevalence and clinical characteristics of congenital thrombophilia in PE patients and their subsequent outcomes. A prospective observational study was conducted from May 2013 to June 2018. A total of 436 consecutive patients with PE were enrolled. All patients were tested for protein C, protein S, antithrombin III (ATIII), factor V Leiden, and prothrombin G20210A mutations. The median follow-up duration was ∼800 days (range, 11-1872 days). Congenital thrombophilia was diagnosed in 31 of 436 (7.1%) patients; 12 patients had protein C deficiency (2.8%), 13 had protein S deficiency (3.0%), 5 had ATIII deficiency (1.1%), and 1 had (0.2%) factor V Leiden. Age ≤50 years at the first episode (odds ratio [OR], 5.43; 95% confidence interval [CI], 2.35-13.52; P &lt; .001) and male sex (OR, 2.67; 95% CI, 1.15-6.78; P = .03) were 2 independent predictors of congenital thrombophilia in PE patients. There was no statistically significant difference in the prevalence of congenital thrombophilia between PE patients with and without risk factors (P = .58). We also found no significant difference in the risk of having a composite outcome of death or recurrent venous thromboembolism between patients with and without congenital thrombophilia (hazard ratio, 0.18; 95% CI, 0.02-5.69; P = .08). These results suggest that age and male sex are independently associated with the occurrence of congenital thrombophilia in PE patients but that congenital thrombophilia is not associated with the risk of recurrence or death with anticoagulation therapy.
Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?
Authors: Chen Evan C. , Garcia Jacqueline S. 
Published: December 2020

Abstract
The treatment choice for newly diagnosed patients with acute myeloid leukemia (AML) is no longer straightforward. Historically, patient fitness has been a major driver of the initial therapy decision based on the belief that intensive chemotherapy would be the optimal choice if a patient were “fit” enough to receive it. Tools based on chronological age, performance status, and comorbidities have been developed to help estimate patient fitness. With newer approved therapies that include nonintensive options such as IDH1 inhibition or less intensive options such as hypomethylating agent (HMA)- or low-dose cytarabine (LDAC)-based combinations with venetoclax, the choice of frontline AML therapy places more emphasis on disease-specific features, including cytogenetics and mutational profile. Moreover, newer treatments have higher response rates than what has been expected with older nonintensive options such as LDAC or HMA monotherapy. We present cases of three patients with AML with varying cytogenetic and molecular risks to demonstrate the important but changing role of patient fitness in the current era of expanding therapeutic options.
Can we use epigenetics to prime chemoresistant lymphomas?
Authors: Amengual Jennifer E. 
Published: December 2020

AbstractChemoresistance remains a challenging clinical problem in the treatment of many lymphoma patients. Epigenetic derangements have been implicated in both intrinsic and acquired chemoresistance. Mutations in epigenetic processes shift entire networks of signaling pathways. They influence tumor suppressors, the DNA-damage response, cell-cycle regulators, and apoptosis. Epigenetic alterations have also been implicated in contributing to immune evasion. Although increased DNA methylation at CpG sites is the most widely studied alteration, increased histone methylation and decreased histone acetylation have also been implicated in stem-like characteristics and highly aggressive disease states as demonstrated in both preclinical models of lymphoma and patient studies. These changes are nonrandom, occur in clusters, and are observed across many lymphoma subtypes. Although caution must be taken when combining epigenetic therapies with other antineoplastic agents, epigenetic therapies have rarely induced clinical meaningful responses as single agents. Epigenetic priming of chemotherapy, targeted therapies, and immunotherapies in lymphoma patients may create opportunities to overcome resistance.
When I treat a patient with acute pulmonary embolism at home
Authors: Klok Frederikus A. , Huisman Menno V. 
Published: December 2020

AbstractHome treatment is feasible and safe in selected patients with acute pulmonary embolism (PE) and is associated with a considerable reduction in health care costs. When establishing a PE outpatient pathway, 2 major decisions must be made. The first one concerns the selection of patients for home treatment. The second one involves dedicated outpatient follow-up including sufficient patient education and facilities for specialized follow-up visits. Current evidence points toward the use of either the Hestia criteria or Pulmonary Embolism Severity Index with/without assessment of the right ventricular function to select patients for home treatment, depending on local preferences. Results from ongoing trials are expected to enforce current guideline recommendations on home treatment and pave the way for more broad application of this elegant and cost-effective management option for patients with acute PE.
Improving symptom control and reducing toxicities for pediatric patients with hematological malignancies
Authors: Sung Lillian , Miller Tamara P. , Phillips Robert 
Published: December 2020

Abstract
The continuing improvement in pediatric cancer survival over time is largely attributable to the availability of intensive therapies. Increasing attention has been focused on addressing the physical and psychosocial impacts of cancer and cancer treatments. Evidence from adult oncology suggests that routine symptom screening and feedback to health care providers can improve patient-clinician communication, reduce distress, and improve quality of life and may even increase survival. Many questions remain regarding implementation of routine symptom screening in pediatric cancer care, including the best symptom assessment instrument and the reporter type and feasibility of integration with electronic health records (EHRs). Nonsymptom adverse events are also important, for both routine clinical care and adverse event reporting for patients enrolled in clinical trials. However, traditional mechanisms for reporting adverse events lead to substantial inaccuracies and are labor intensive. An automated approach for abstraction from EHRs is a potential mechanism for improving accuracy and reducing workload. Finally, identification of symptom and nonsymptom toxicities must be paired with prophylactic and therapeutic strategies. These strategies should be based on clinical practice guidelines that synthesize evidence and use multiprofessional, multidisciplinary expertise to place this evidence in clinical context and create recommendations. How best to implement clinical practice guidelines remains a challenge, but EHR order sets and alerts may be useful. In summary, although survival is excellent for pediatric patients receiving cancer therapies, more focus is needed on identification of symptoms and nonsymptom toxicities and their management. The EHR may be useful for promoting better supportive care through these mechanisms.
Patient stratification in myelodysplastic syndromes: how a puzzle may become a map
Authors: Kubasch Anne Sophie , Platzbecker Uwe 
Published: December 2020

Abstract
Heterogeneity is the disease-defining epithet of myelodysplastic syndromes (MDS), a clonal disorder of hematopoietic stem and progenitor cells. During the last decade, significant progress has been made to better understand the diversity of clinical, molecular, cellular, and immunological factors that are bound to the prognosis and outcomes of patients with MDS. Despite the rapid generation of all of this biological information, how to implement it has fallen short. Redefining clinical tools to use this new information remains a challenge. The holistic integration of novel, high-impact individual risk parameters such as patient-reported outcomes or mutational and immunological data into conventional risk stratification systems may further refine patient subgroups, improve predictive power for survival, and provide a next-generation classification and prognosis system for patients with MDS. Dichotomic treatment strategies in patients with MDS according to their patient and disease profiles highlight the importance of precise risk stratification, which may be complemented by the definition of granular cohorts of patients with myeloid neoplasms and a druggable target (ie, IDH1/2 mutations) across conventional blast thresholds.
Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management
Authors: McLintock Claire 
Published: December 2020

Abstract
Postpartum hemorrhage (PPH) is the leading cause of global maternal mortality and accounts for approximately one-quarter of all maternal deaths worldwide. Prevention of excess maternal deaths requires a coordinated approach to prevention, early recognition, and intervention by a multidisciplinary team. Although some women have risk factors for PPH that can be identified during pregnancy or during labor or birth, most women with severe PPH do not have any risk factors. Therefore, all pregnant women must be considered to be at risk of PPH. Common causes include uterine atony, retained placenta, trauma to the genital tract or uterus, and coagulopathy. The pivotal role of fibrinogen and hyperfibrinolysis in the evolution and as a treatment target for PPH is increasingly recognized. Coagulopathy can be an early feature in PPH that may be unrecognized, as it can be present before massive transfusion has occurred. Identification of coagulopathy by viscoelastic point-of-care testing or conventional laboratory assays can be helpful in guiding management of PPH and preventing severe maternal outcomes.
Immunotherapy with drugs
Authors: Choi Yun , Diefenbach Catherine S. 
Published: December 2020

Abstract
The treatment of lymphomas has undergone a shift in the last few decades, from traditional cytotoxic chemotherapy toward immune-targeting agents that supplement or, in some cases, even supplant direct tumor killing with activation of antitumor systemic immunity. Since the introduction of the first known immunomodulatory modality, allogeneic hematopoietic cell transplantation, multiple immunotherapeutic approaches have been developed including monoclonal antibodies (mABs), antibody-drug conjugates, bispecific T-cell engagers, checkpoint inhibitors, small molecule inhibitors, chimeric antigen receptor (CAR) T-cell therapies, and vaccines. Many of these agents, either as monotherapies or as a component of a combination strategy, have shown impressive results, combining efficacy with tolerability. Immunotherapy ranging from mABs to checkpoint inhibitors and CAR T-cell therapy are now integrated into lymphoma treatment from the earliest lines of therapy to the relapsed and refractory setting for both Hodgkin (HL) and non-Hodgkin lymphoma (NHL). Although further studies are needed to improve our understanding of the unique side effects of immunomodulation, to determine the optimal sequence and combinations of these agent with targeted therapies and standard chemotherapy, and to identify predictive biomarkers, they clearly represent a growing list of treatment options for both HL and NHL and an important step on our road toward cure of these diseases.
Role of venous stenting for venous thromboembolism
Authors: Breen Karen 
Published: December 2020

AbstractEndovenous stenting has emerged as the method of choice to treat iliofemoral venous outflow obstruction. It is used in patients with established postthrombotic syndrome (PTS) after previous deep vein thrombosis (DVT) to reduce symptoms of chronic pain and swelling and to aid ulcer healing in severe cases. Venous stenting is used to alleviate symptoms of obstruction in patients presenting with acute DVT, with the aim of preventing development of PTS. There is a low risk of morbidity and mortality associated with the use of endovenous stenting, and although significant advances have been made, particularly improvements in stent design for use in the venous circulation, data are lacking on beneficial long-term outcomes. Unmet research needs include optimal patient selection, anticoagulant choice and duration, best practice for postoperative surveillance, and use of validated assessment tools to measure outcomes. In this article, I address the potential benefits, as well as the challenges, of endovenous stenting.
Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs
Authors: Engel Elissa R. , Walter Jolan E. 
Published: December 2020

Abstract
Rituximab and eculizumab, monoclonal antibodies that deplete most B cells and activate the terminal complement, respectively, are used to treat nonmalignant hematologic disorders (NMHDs), sometimes with unfavorable effects on the immune system. Hypogammaglobulinemia and neutropenia have been reported with variable prevalence in patients treated with rituximab. Neutropenia is mild and transient, and serious infectious complications are uncommon, so treatment is not indicated. Hypogammaglobulinemia is of greater concern. There is a lack of agreement on a standardized definition, and pre- and posttreatment immunoglobulin (Ig) levels are not routinely obtained. The association among low Ig levels, infectious risk, and mortality and morbidity in this population is unclear. There are also no formal guidelines on indication, risk factors, and threshold level of IgG to prompt Ig replacement therapy (IgRT). Among patients with NMHD, preexisting or persistent hypogammaglobulinemia (PH) after treatment with rituximab has been linked to underlying primary immunodeficiency disorders; therefore, a high index of suspicion should be maintained, and immunologic and genetic evaluation should be considered. Overall, important strategies in managing patients who are receiving rituximab include routine monitoring of pre- and posttreatment IgG levels, immune reconstitution (eg, B-cell subsets), assessment of vaccination status and optimization before treatment, and individualized consideration for IgRT. Accordingly, we discuss immunizations. Eculizumab, most commonly used in the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, poses increased risk of meningococcal infections. To decrease the risk of infection, a meningococcal vaccination series is recommended before initiating therapy, and prophylactic antibiotics are preferred during the course of treatment.
How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation
Authors: Abraham Roshini S. 
Published: December 2020

Abstract
The identification of genetic disorders associated with dysregulated immunity has upended the notion that germline pathogenic variants in immune genes universally result in susceptibility to infection. Immune dysregulation (autoimmunity, autoinflammation, lymphoproliferation, and malignancy) and immunodeficiency (susceptibility to infection) represent 2 sides of the same coin and are not mutually exclusive. Also, although autoimmunity implies dysregulation within the adaptive immune system and autoinflammation indicates disordered innate immunity, these lines may be blurred, depending on the genetic defect and diversity in clinical and immunological phenotypes. Patients with immune dysregulatory disorders may present to a variety of clinical specialties, depending on the dominant clinical features. Therefore, awareness of these disorders, which may manifest at any age, is essential to avoid a protracted diagnostic evaluation and associated complications. Availability of and access to expanded immunological testing has altered the diagnostic landscape for immunological diseases. Nonetheless, there are constraints in using these resources due to a lack of awareness, challenges in systematic and logical evaluation, interpretation of results, and using results to justify additional advanced testing, when needed. The ability to molecularly characterize immune defects and develop “bespoke” therapy and management mandates a new paradigm for diagnostic evaluation of these patients. The immunological tests run the gamut from triage to confirmation and can be used for both diagnosis and refinement of treatment or management strategies. However, the complexity of testing and interpretation of results often necessitates dialogue between laboratory immunologists and specialty physicians to ensure timely and appropriate use of testing and delivery of care.